Primary Site >> Stomach Cancer
Gene >> CDAN1
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. PMID: 14676796 Ref: Phase I and Pharmacokinetic Study of Intraoperative Intraperitoneal Heptaplatin in Patients with Surgically Resected Advanced Gastric Cancer. PMID: 26680911 |
Ref: Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. PMID: 14998859 Ref: Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. PMID: 15138468 Ref: Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. PMID: 15238990 Ref: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. PMID: 15274365 Ref: [Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer]. PMID: 15570920 |
Ref: Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. PMID: 15613903 Ref: [A phase I study of TS-1 and weekly cisplatin in patients with advanced gastric cancer]. PMID: 15918563 Ref: Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer. PMID: 16042786 Ref: Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). PMID: 16141295 Ref: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. PMID: 16145066 Ref: Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. PMID: 16319513 |
Ref: A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer. PMID: 16619558 Ref: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. PMID: 16773074 |
Ref: Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial. PMID: 17377918 Ref: [A phase I study of postoperative combination therapy with TS-1 and low dose cisplatin against stage IV gastric carcinoma]. PMID: 17431342 Ref: Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. PMID: 17450468 Ref: Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. PMID: 17695429 Ref: A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method. PMID: 18211983 |
Ref: Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age. PMID: 18481067 |
Ref: Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. PMID: 19936751 Ref: Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis. PMID: 21372602 |
Ref: Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. PMID: 20839031 Ref: Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. PMID: 21853311 Ref: Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer. PMID: 22752217 |
Ref: Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients. PMID: 22669361 Ref: Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. PMID: 23930209 Ref: Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. PMID: 24091982 |
Ref: Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. PMID: 24574780 Ref: Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer. PMID: 24649314 Ref: Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. PMID: 25107918 |
Ref: A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA). PMID: 25486878 Ref: Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. PMID: 25687867 Ref: Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. PMID: 25715763 |
Ref: Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: A phase-I clinical trial. PMID: 28413680 Ref: A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. PMID: 28973403 |
Ref: A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer. PMID: 30089457 Ref: Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. PMID: 30350178 |